Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 25, 2010
Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will...
-
Mar 12, 2010
Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces that it has entered into a licensing agreement with the Johns Hopkins University's...
-
Mar 11, 2010
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic...
-
Jan 19, 2010The DVTeamCare™ Hospital Award Provides National Recognition for Deep Vein Thrombosis Prevention Programs
The North American Thrombosis Forum (NATF), in coordination with Eisai Inc., announced today that three hospitals have been selected as recipients of the 2009 DVTeamCare Hospital Award. This new...
-
Jan 6, 2010Eisai Completes Acquisition of AkaRx, Inc. and Continues Development of AKR-501 for Thrombocytopenia
Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces the successful completion of its acquisition of the biopharmaceutical company,...
-
Nov 24, 2009
Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl...
-
Nov 16, 2009
Eisai Inc. today announced that LUSEDRA™ (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution,...
-
Nov 11, 2009Eisai Employees, in Cooperation with the Foundation for Hospital Art, Create Artwork to Help Improve the Lives of Patients and Families
Eisai Inc. today announced that it has donated more than 80 pieces of artwork, created by its employees, to hospitals across the United States. The multi-panel murals were created by more than...
-
Oct 30, 2009Eisai Plans to Submit Marketing Authorization Applications for Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer
Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced...
-
Oct 29, 20092009 C.A.R.E. (Commitment to Alzheimer's. Recognition of Excellence.) Pharmacy Award Acknowledges Excellence in Alzheimer's Disease Education and Patient Care
Eisai Inc. and the Alzheimer's Association announce today that Heather Greene, PharmD is the recipient of the 2009 C.A.R.E. Pharmacy Award. (Photo: http://www.newscom.com/cgi-bin/prnh/20091029/NY00986